본문 바로가기

Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q4Scopus Q2
피인용
Web of Science 3
JCR IF
JCR 2011 1.183
ISSN
0946-1965

저자

  1. Noh, Yook-Hwan제1저자울산대학교, Asan Med Ctr, Coll Med, KO
  2. Lim, Hyeong-Seok울산대학교, Asan Med Ctr, Coll Med, KO
  3. Cho, Sang-Heon울산대학교, Asan Med Ctr, Coll Med, KO
  4. Ghim, Jong-Lyul인제대학교, Dept Clin Pharmacol, KO
  5. 최상민부산대학교, 부산대학교병원, 대학병원, KO
  6. Jung, Jin Ah성균관대학교, Sch Med, Samsung Med Ctr, KO
  7. Kim, Mi Jo울산대학교, Asan Med Ctr, Coll Med, KO
  8. Kim, Yo Han울산대학교, Asan Med Ctr, Coll Med, KO
  9. Jin, Seok-Joon울산대학교, Asan Med Ctr, Coll Med, KO
  10. Kim, Soon Bae울산대학교, Asan Med Ctr, Coll Med, KO
  11. Park, Jung Sik울산대학교, Asan Med Ctr, Coll Med, KO
  12. Lee, Sang Koo울산대학교, Asan Med Ctr, Coll Med, KO
  13. Yang, Won Seok울산대학교, Asan Med Ctr, Coll Med, KO
  14. Chang, Jai Won울산대학교, Asan Med Ctr, Coll Med, KO
  15. Lee, BongyongSK, Life Sci R&D Ctr, KO
  16. Bae, Kyun-Seop교신저자울산대학교, Asan Med Ctr, Coll Med, KO

초록

Objective: To evaluate and compare the pharmacokinetics and tolerability of a single oral dose of mirodenafil in volunteer patients with severe renal impairment and healthy volunteers. Methods and materials: This open-label, single-dose, parallel-group clinical study enrolled a total 12 volunteers (6 healthy volunteers and 6 volunteer patients with severe renal impairment). Each volunteer was orally administered 50 mg mirodenafil and serial blood samples were obtained after drug administration to determine the plasma concentration of mirodenafil using LC-MS/MS. The measured individual plasma concentrations were used to calculate the pharmacokinetic parameters using noncompartmental methods. Tolerability was also assessed using measurements of vital signs, clinical chemistry tests, and interviews. Results: All of the volunteers completed the study with no serious adverse events (AEs). A total of 4 AEs were reported, but all were of mild or moderate intensity and not considered to be related to the study drug. The geometric mean (95% CI) of the terminal half-life (t(1/2 beta)) and the apparent clearance (CL/F) values of mirodenafil were 2.2 (1.4 - 3.4) hours and 127.2 (95.1 - 170.2) 1/h in the volunteer patients, and 3.0 (2.1 - 4.4) hours and 136.1 (74.4 - 249.2) 1/h in the healthy volunteers, respectively. The geometric mean of the AUC(0-t) of the volunteer patients was 8% higher and the geometric mean for clearance was 7% lower compared with the healthy volunteers. However, the geometric mean of the C-max of the volunteer patients was 38% higher than that of the healthy volunteers. Conclusions: A single oral 50-mg dose of mirodenafil was well tolerated. Exposure (AUC(0-t)) to mirodenafil was similar in both healthy volunteers and volunteer patients with severe renal impairment and healthy volunteers.

키워드

mirodenafilphosphodiesterase 5 (PDE5) inhibitorrenal impairmentpharmacokineticshealthy volunteersERECTILE DYSFUNCTION5 INHIBITORSK3530EFFICACYSAFETYMEN

식별자

WoS UID
000313595100005